Cancer of the Esophagus
Conditions
Keywords
Adenocarcinoma, Squamous cell carcinoma, Gastroesophageal Junction
Brief summary
This study compares outcomes with regard to the timing of resective surgery after neoadjuvant chemoradiotherapy (CRT) in cancer of the esophagus or gastric cardia. Patients are randomised to surgery either conventional 4-6 or 10-12 weeks after termination of CRT. The study hypothesis is that a longer delay improves histological response and decreases the risk of postoperative morbidity and mortality.
Interventions
PROCEDUREResective surgery
Sponsors
Oslo University Hospital
Lund University Hospital
Sahlgrenska University Hospital
Region Örebro County
University Hospital, Umeå
St. Olavs University Hospital
University Hospital, Linkoeping
University Hospital of North Norway
University Hospital Cologne
Karolinska University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Histologically verified adenocarcinoma or SCC of the esophagus or GEJ Siewert type I and II. * Tumors should be resectable and without distant metastasis, as assessed after completed CRT. * Patients with performance status 0-1 according to the Eastern Cooperative Oncology Group (ECOG) scale at the pre CRT evaluation and judges to be fit for surgery at the pre and post CRT evaluations. * Pre CRT tumor stage: T1N1-3M0, T2N0-3M0, T3N0-3,M0, T4aN0-3,M0 * Written informed consent * Completed at least 80% of the planned chemotherapy and at least 90% of the prescribed radiotherapy dose within the neoadjuvant CRT schedule according to protocol within a period of \<36 days.
Exclusion criteria
* Concomitant malignant diagnosis (excluding non-melanoma skin cancer) \<5 years since current cancer diagnosis. * Ongoing antitumoral treatment irrespective of time since diagnosis of earlier malignancy. * Patients being unable to comply with the protocol for reasons of language or cognitive function. * Tumor stage T1N0, T4bNX or TXNXM1. * Carcinoma of the upper third of the esophagus (i.e. cervical and uppermost thoracic) for simplicity here defined as upper border of tumor above 22 cm from incisors at endoscopy. * Clear radiological signs of tumor progression during CRT on CT-scan after completion of CRT. PET is not used in this decision as FDG-activity often increase due to radiotherapy induced inflammation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete histological response proportion, using the Chirieac grading system. | analysis is completed 4 weeks after surgery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between symptom scores, endoscopy and radiology; and complete histological response. | 4 weeks after surgery | — |
| Health-related quality of life (HRQOL). | 4-6 or 10-12 weeks prior to surgery (at randomization after completed CRT), within a week before surgery, 6 months postoperatively, 12 months postoperatively and then yearly until 5 years of follow-up. | Validated questionnaires that assess patients functions (physical, emotional, social, role and cognitive function), symptoms (e.g. fatique, pain, nausea/vomiting, appetite, dysphagia, eating difficulties and diarrhea) and global quality of life. |
| Overall primary tumor treatment response defined as complete histological response (Chirieac 0) and partial histological response (Chirieac 1 and 2) together. | analysis is completed 4 weeks after surgery | — |
| ypN tumor status, classified as ypN0 to ypN3. | analysis is completed 4 weeks after surgery | — |
| 5 year survival by intention to treat and per protocol analyses in each study arm. | 5 years | — |
| QUALYs at 5 year follow-up in each study arm. | 5 years after surgery | Quality Adjusted Life Year assesses not only how much longer the treatment will allow the patient to live, but weighs in the quality of life with survival as a composite variable. |
| R0 resection rate in each study arm. | analysis is completed 4 weeks after surgery | — |
| Resectability rate in each study arm. | 4-6 or 10-12 weeks after completed CRT | — |
| Safety and toxicity (only grade 3-5 toxicity will be reported) ety and toxicity (only grade 3-5 toxicity will be reported) | 4-6 or 10-12 weeks after completed CRT | According to Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 |
| Postoperative complications in each study arm. | 30 days after surgery | Using the classification in the Swedish National Registry for Gastric and Esopgageal Cancer (NREV), including Clavien-Dindo classification. |
| Nutritional status of patients in each study arm. | within a week before the start of CRT, within a week before surgery and 5 years after surgery | — |
| Proportion of disease free patients after 5 years by intention to treat and per protocol analyses in each study arm. | 5 years | — |
Countries
Sweden
Outcome results
None listed